1,010,520 Shares in Ralliant Corporation $RAL Bought by Rokos Capital Management LLP

Rokos Capital Management LLP purchased a new stake in shares of Ralliant Corporation (NYSE:RAL) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,010,520 shares of the company’s stock, valued at approximately $42,022,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Danske Bank A S acquired a new stake in Ralliant in the 4th quarter worth $25,000. V Square Quantitative Management LLC bought a new stake in shares of Ralliant in the 4th quarter valued at approximately $26,000. Allworth Financial LP raised its holdings in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new position in shares of Ralliant during the 3rd quarter worth approximately $26,000. Finally, BOKF NA bought a new position in shares of Ralliant during the 3rd quarter worth approximately $29,000.

Ralliant Stock Up 0.5%

Shares of RAL opened at $69.75 on Tuesday. The company has a market capitalization of $7.81 billion and a P/E ratio of -6.38. Ralliant Corporation has a one year low of $37.27 and a one year high of $75.41. The business’s 50 day simple moving average is $66.65 and its 200-day simple moving average is $53.94. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts predict that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.

Wall Street Analysts Forecast Growth

RAL has been the topic of a number of analyst reports. Evercore initiated coverage on Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target on the stock. Truist Financial reissued a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. BMO Capital Markets began coverage on shares of Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Finally, Oppenheimer increased their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $73.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.